Wantai COVID-19 Total antibody ELISA
Total antibody detection for high sensitivity
Uses S1 RBD ( Receptor Binding Domain) for high specificity
US FDA authorized
Best ELISA kit as recommended by WHO
COVID -19 TESTS
Fast Results- Results within 75 minutes
Antigen coating- S1 RBD antigen coating for neutralizing antibody detection with high specificity
Total antibody detection- IgG+ IgM detection thus providing better screening tool with enhanced sensitivity
Sample Type Serum/Plasma
Controls 2 level controls viz. Positive and negative controls provided
Cost efficient- Breakaway microwells for ease of use
Excellent performance ( As per ICMR evaluation)
Easy procedure Ready to use reagents for user friendliness
Best performing COVID kits as recommended by WHO*
(* Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection, Version: 2.0, Date: 26 May 2020, Contact: EarlyInvestigations-2019-nCoV@who.int)
Quality Approved ICMR approved, CE marked, US FDA approved and IVD approved
HIGH QUALITY RESULTS WITH EXTENSIVELY EVALUATED KIT
In ICMR NIV Evaluation Sensitivity of 98% and Specificity of 100% if found
In the United States, validation study conducted by the National Cancer Institute (NCI) showed sensitivity of 96.7% (29/30) and specificity of 97.5% (78/80) of the test.
WANTAI SARS-CoV-2 Ab ELISA received FDA Emergency Use Authorization on August.05,2020. HCP, Recepients,
In the Netherlands, reporting by the Dutch Serology Taskforces shows sensitivity of the kit of 98.1% for samples collected > 14 days after onset of illness, the Dutch Serology Taskforce report can be downloaded from HERE. In other studies conducted in the Netherlands, Erasmus Medical Center showed sensitivity of 98% (100% >14days) and Sanquin Blood Bank calculated PPV of 99%, 88%, and 72% in areas with prevalence of 4-10%, 2-4%, and <2%.
Statens Serum Institut in Denmark showed sensitivity of 71% (7~13days) ~ 100% (10days) . Also in Denmark, multicentre comparison study ranked Wantai SARS-CoV-2 Ab ELISA as the top serology assay among 15 commercially evaluated tests including automated immunoassays.